FDA Expands Anthrax Vaccine Approval

Share this content:
FDA Expands Anthrax Vaccine Approval
FDA Expands Anthrax Vaccine Approval

TUESDAY, Nov. 24, 2015 (HealthDay News) -- U.S. Food and Drug Administration approval for the BioThrax anthrax vaccine has been expanded to include adults aged 18 to 65 with known or suspected exposure, the agency said in a media release. The vaccine was first approved in 1970 for people at high risk of anthrax contact.

Expanded approval for the injected vaccine was granted under the agency's "animal rule," which states animals may be used to test a drug or product for purposes that aren't ethical or feasible among people, the FDA said.

The BioThrax vaccine was tested on exposed rabbits and deemed to provide a "reasonable level of protection," by providing a survival rate of 70 to 100 percent, the agency said. Adverse reactions among people who have been given the vaccine for pre-disease prevention have included tenderness, pain, swelling, and redness at the injection site; muscle aches; headache; and fatigue.

"With today's approval of BioThrax, we now have a vaccine that can be used, together with antibiotic treatment, to prevent disease after exposure to anthrax spores," Karen Midthun, M.D., director of the FDA's Center for Biologics Evaluation and Research, said in a statement.

BioThrax is produced by Michigan-based Emergent BioDefense Operations Lansing LLC.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Florida Teen First Human Case of Another Mosquito-Borne Virus

Florida Teen First Human Case of Another Mosquito-Borne ...

First documented case of Keystone infection in a human

70 Sickened So Far in Salmonella-Tainted Melon Outbreak

70 Sickened So Far in Salmonella-Tainted Melon Outbreak

Illnesses reported in Illinois, Indiana, Kentucky, Michigan, Missouri, Ohio, and Tennessee

AAFP Still Recommends CRC Screening From Age 50 to 75

AAFP Still Recommends CRC Screening From Age 50 ...

Despite ACS change to start screening from age 45 years, AAFP agrees with USPSTF recommendation

is free, fast, and customized just for you!




Already a member?

Sign In Now »